Viral Vaccines and Cell Substrate: A “Historical” Debate

  • Florian Horaud


The article by S. Plotkin concerning the history of rubella vaccines and the cell substrate is an excellent illustration of the “ballet” performed around the problem of the acceptability criteria of cell substrate used in the development and preparation of viral vaccines. This problem came to my attention many years ago when I worked in the World Health Organization (WHO) experts groups, but in the last decade this topic had been an important concern for me since I act as an expert in virology operating in French and European regulatory systems.


Viral Vaccine Vero Cell Primary Cell Culture Cell Substrate Continuous Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Horaud F. Viral safety of biologicals. Dev Biol Stand 1991;75:3–7PubMedGoogle Scholar
  2. 2.
    Enders JF, Weller TH, Robbins FC. Cultivation of Lansing strain of poliomyelitis virus in culture in various human embryonic tissues. Science 1949;109:86–7CrossRefGoogle Scholar
  3. 3.
    Keereti S, Nathanson N. Human exposure to SV40: review and comment. Am J Epidmiol 1976;103:1–12Google Scholar
  4. 4.
    Hayflick L. History of the cell substrates used for human biologicals. Dev Biol Stand 1989;70:11–26PubMedGoogle Scholar
  5. 5.
    US Department of Health, Education and Welfare, Public Health Service. Regualtion for the Manufacture of Biological Products, title 42, part 73. DHEW publication no (NIH) 71–161, formerly PHS publication no 437, revised 1971–1976Google Scholar
  6. 6.
    Petricciani J, Hopps H, Chapple PJ eds. Cell substrates: their use in the production of vaccines and other biologicals. In: Advances in Experimental Medicine and Biology 118:9–21, New York: Plenum Press, 1979Google Scholar
  7. 7.
    Finter NB, Fantes KH, Lockier MJ, Lewis GD, Ball GD. The DNA content of crude and purified human interferon prepared by Wellcome Biotechnology Limited. In: Hopps HE, Petricciani JC, eds. Abnormal Cells, New Product and Risk. In vitro Cellular & Development Biology, Tissue Culture Association USA. 1985; monograph no 8:125–8Google Scholar
  8. 8.
    Van Wezel AL. Growth of cell strain and primary cells on micro carriers in homogenous culture. Nature 1967;216:65–5CrossRefGoogle Scholar
  9. 9.
    Montagnon BJ. Polio and rabies vaccines produced in continuous cell line: a reality for Vero cell line. Dev Biol Stand 1988;70:27–47Google Scholar
  10. 10.
    Petriccianni J. Cell, products, safety: background papers from the WHO Study Group on biologicals. Dev Biol Stand 1987;68:43–9Google Scholar
  11. 11.
    Horaud F. Viral vaccines and residual cellular DNA. Biologicals 1995;23:225–8PubMedCrossRefGoogle Scholar
  12. 12.
    Petricciani J, Horaud F. DNA, dragons and sanity. BiologicalsI 1995;23:233–8CrossRefGoogle Scholar
  13. 13.
    Horaud F. Absence of viral sequnces in the WHO-Vero cell bank: a collaboration study. Dev Biol Stand 1992;76:43–6PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Florian Horaud
    • 1
  1. 1.Paris cedex 15France

Personalised recommendations